Selected Grants
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
Clinical TrialPrincipal Investigator · Awarded by ONL Therapeutics · 2025 - 2030A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)
Clinical TrialPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2025 - 2030A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Clinical TrialPrincipal Investigator · Awarded by Ocugen, Inc. · 2024 - 2029Screening for Advanced Dry Age-Related Macular Degeneration in assisted living centers
Clinical TrialCo-Principal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2023 - 2028Learning-based 3D modeling of AMD to assess disease progression and response to treatment
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2027Augmented Reality Guidance using Digital Twin-based Virtual Simulator for Retinal Laser Therapy
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2024 - 2026A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2022 - 2025External Relationships
- ADVERUM
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Allergan, AbbVie Company
- Apellis
- Bausch & Lomb, Inc.
- Iveric Bio
- Ocugen, Malvern, PA
- Ocular Therapeutix Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.